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data. Costs and beneﬁts were discounted at 5% per annum as per
Hungarian guidelines. RESULTS: With reference to the ATTAIN
trial, and assuming a treatment duration of 1 year and 10 years
time horizon, abatacept was cost-effective compared to MTX,
yielding 0.57 additional QALY at an additional cost of 2.03
million HUF with an incremental cost-effectiveness ratio of 3.6
million HUF/QALY based on a societal perspective. From the
Hungarian health insurance perspective, the incremental cost-
effectiveness ratio was 4.4 million HUF/QALY gained. Com-
pared to cycled anti-TNFs, abatacept was dominant (more
effective and overall less costly), with a QALY gain of 0.48 and
estimated savings of HUF 731113. From the Hungarian health
insurance perspective, the savings were 479 815 HUF. The results
are robust to extensive sensitivity analyses. CONCLUSIONS:
The results of this cost-utility assessment suggest that abatacept
is cost-effective compared to MTX and to cycled anti-TNFs in
Hungary for the approved indication, and within the usual
acceptance cost-effectiveness ranges.
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OBJECTIVES: To evaluate the effect of golimumab (GLM) treat-
ment on time lost from work in rheumatoid arthritis (RA)
patients. METHODS: The effect of GLM on time lost from work
was evaluated in three multicenter, randomized, double-blind,
placebo (PBO)-controlled RA studies (GO-BEFORE,
GO-FORWARD, and GO-AFTER). Data from patients receiving
GLM or PBO with or without methotrexate (MTX) were
included. GLM SC injections of 50 mg or 100 mg were admin-
istered q4wks. Analyses were pooled to increase the power to
detect a difference between treatment groups. Time lost from
work was collected through a questionnaire at baseline and
q8wks through wk24. Time lost from work was summarized
cumulatively through wk16 and wk24 and compared between
groups using an ANOVA on van der Waerden normal scores. The
analysis was limited to patients <65 years of age and employed
full-time at baseline. The proportion of patients reporting no
days lost from work in the GLM +/-MTX group compared with
PBO +/-MTX was calculated and compared between groups
using chi-square test. RESULTS: There were signiﬁcant differ-
ences in time lost from work (days) for patients treated with
GLM +/-MTX through wk16 and wk24 compared with PBO +/-
MTX. At wk24, the PBO +/-MTX group had lost on average 6.9
 19.7 days compared with 5.0  19.4 days for the combined
GLM +/-MTX group, a difference of 1.9 days (p = 0.004). At wk
24, the 75th percentile for the combined GLM +/-MTX group
was 1.000 day (range 0–180) compared with 3.000 days (range
0–120) for the PBO +/-MTX group. A signiﬁcantly higher
proportion of patients in the combined GLM +/-MTX group
reported no time (days) lost from work compared with PBO
+/-MTX (73.1% vs. 60.7%; p = 0.002). CONCLUSIONS: GLM
+/-MTX signiﬁcantly reduced time lost from work for RA
patients compared with PBO +/-MTX. A signiﬁcantly higher
proportion of patients in the GLM group reported no time lost
from work compared with PBO +/-MTX.
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OBJECTIVES: To describe the multidisciplinary outpatient man-
agement of ﬁbromyalgia and the paramedical resources and alter-
native treatments used in France, METHODS: A French expert
panel, involving 33 general practitioners (GP) and 27 rheuma-
tologists, was asked to describe their prescribed paramedical care
and other alternative treatments in ﬁbromyalgia patients, by
means of a questionnaire covering a period of four years before
diagnosis to four plus years after diagnosis, with 1-year intervals.
Average reported prescriptions were calculated. Costs were cal-
culated by multiplying prescribed resource use with correspond-
ing French unit costs (€; 2007; societal perspective). RESULTS:
Paramedical resource use and other alternative treatments
increase substantially as from year from four years untill the ﬁrst
year after diagnosis, and slightly decrease in the subsequent
years. In the ﬁrst year after ﬁbromyalgia diagnosis, 20% of the
panel prescribes various food supplements in 59% of their
patients (average duration varying between 8 and 52 weeks);
93% prescribes physiotherapy in 63% of their patients (average
duration of 14 weeks); 57% prescribes thermal baths in 23% of
their patients (3 weeks); 55% prescribes acupuncture in 30% of
their patients (14 weeks); 48% prescribes chiropractor therapy in
28% of their patients (8 weeks); 55% prescribes relaxation
therapy in 24% of patients (17 weeks); 37% prescribes psycho-
analysis in 21% of patients (28 weeks); 20% prescribes hypno-
therapy in 16% of patients (9 weeks); 8% prescribes biofeedback
in 16% of patients (20 weeks). The average cost from a societal
perspective is estimated at €387 per patient per year, ranging
from €265 before diagnosis (4 year period), over €678 in the year
following diagnosis, towards €453 in the period after diagnosis
(3 year period). CONCLUSIONS: Paramedical and alternative
treatment of ﬁbromyalgia represents 387 euros per patient and
per year from the societal perspective. Resource use and costs
steadily increase till the year following diagnosis and decline
afterwards.
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OBJECTIVES: To describe and compare the outpatient medical
management of ﬁbromyalgia patients in France and United-
Kingdom, METHODS: A French expert panel, involving 33
general practitioners (GPs) and 27 rheumatologists, was ques-
tioned in 2007 by means of a questionnaire describing the UK
prescriptions registered in the General Practice Research Data-
base between January 1998 and March 2003. Participating
experts were asked to describe their own clinical practice com-
pared to the UK prescriptions in terms of diagnostic tests, drugs,
consultations and referrals. over a period of four years before
diagnosis to four plus years after diagnosis using one year inter-
vals. Average reported prescriptions were calculated and com-
pared to the UK data. RESULTS: Interviewed experts monitor on
average 36 [24–49] ﬁbromyalgia patients, of whom 38% [31–47]
for at least 4 years. Their patients have an average age of 48
[47–49] (vs 49 in UK), 86% [84–88] are women (vs 81% in UK).
French physicians are 74.4% [73.3–75.6] likely to validate the
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